NASDAQ:IMUX Immunic (IMUX) Stock Price, News & Analysis $1.11 +0.03 (+2.78%) (As of 09:40 AM ET) Add Compare Share Share Today's Range$1.10▼$1.1250-Day Range$0.98▼$1.3852-Week Range$0.95▼$2.82Volume3,478 shsAverage Volume616,297 shsMarket Capitalization$99.99 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immunic alerts: Email Address Immunic MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside687.0% Upside$8.50 Price TargetShort InterestHealthy3.29% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.94) to ($0.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.35 out of 5 starsMedical Sector683rd out of 879 stocksPharmaceutical Preparations Industry319th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingImmunic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunic has received no research coverage in the past 90 days.Read more about Immunic's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.29% of the outstanding shares of Immunic have been sold short.Short Interest Ratio / Days to CoverImmunic has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.Change versus previous monthShort interest in Immunic has recently decreased by 22.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmunic does not currently pay a dividend.Dividend GrowthImmunic does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMUX. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 5 people have searched for IMUX on MarketBeat in the last 30 days. This is a decrease of -58% compared to the previous 30 days.MarketBeat Follows4 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunic insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Immunic is held by insiders.Percentage Held by Institutions51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunic's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immunic are expected to grow in the coming year, from ($0.94) to ($0.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunic is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunic is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunic has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immunic's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About Immunic Stock (NASDAQ:IMUX)Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Read More IMUX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMUX Stock News HeadlinesMay 28, 2024 | prnewswire.comImmunic to Participate in Industry and Scientific Conferences in JuneMay 23, 2024 | investorplace.comPeek Behind the Curtain: 7 Penny Stocks With Heavy Insider BuyingJuly 8, 2024 | Colonial Metals (Ad)The asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Retirement Protection Kit, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.May 21, 2024 | theglobeandmail.comImmunic CMO discusses role of clinical trials in biotech development for Clinical Trials DayMay 10, 2024 | markets.businessinsider.comHold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial OutlookMay 9, 2024 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comWe Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth CarefullyMay 8, 2024 | msn.comIMUX Stock Earnings: Immunic Misses EPS for Q1 2024July 8, 2024 | Colonial Metals (Ad)The asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Retirement Protection Kit, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.May 8, 2024 | proactiveinvestors.comImmunic advances ‘potentially groundbreaking' MS therapy vidofludimus calcium during Q1May 8, 2024 | prnewswire.comImmunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | msn.comImmunic Q1 2024 Earnings PreviewMay 6, 2024 | prnewswire.comImmunic to Participate in Investor and Scientific Conferences in MayMay 3, 2024 | benzinga.comImmunic Stock (NASDAQ:IMUX), Quotes and News SummaryMay 1, 2024 | prnewswire.comImmunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdateApril 30, 2024 | proactiveinvestors.comImmunic publishes extended data from Phase 2 MS trial in peer-reviewed journalApril 30, 2024 | prnewswire.comImmunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationApril 29, 2024 | finance.yahoo.comImmunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial roleSee More Headlines Receive IMUX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMUX CUSIPN/A CIK1280776 Webwww.immunic-therapeutics.com Phone(332) 255-9818Fax858-673-6843Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$8.50 High Stock Price Target$10.00 Low Stock Price Target$7.00 Potential Upside/Downside+687.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-161.82% Return on Assets-118.57% Debt Debt-to-Equity RatioN/A Current Ratio5.09 Quick Ratio5.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book1.69Miscellaneous Outstanding Shares90,080,000Free Float87,377,000Market Cap$97.29 million OptionableOptionable Beta1.77 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Duane D. Nash J.D. (Age 53)M.B.A., M.D., Executive Chairman Comp: $504.57kDr. Daniel Vitt Ph.D. (Age 56)CEO, President & Director Comp: $869.96kMr. Glenn Whaley CPA (Age 56)Chief Financial Officer Comp: $576.85kDr. Andreas Muehler M.D. (Age 59)Ph.D., Chief Medical Officer Comp: $694.86kDr. Hella Kohlhof (Age 50)Chief Scientific Officer Jessica BreuHead of Investor Relations & CommunicationsMr. Inderpal Singh (Age 57)General Counsel Mr. Patrick Walsh (Age 40)Chief Business Officer More ExecutivesKey CompetitorsAeglea BioTherapeuticsNASDAQ:AGLEHeron TherapeuticsNASDAQ:HRTXAcelyrinNASDAQ:SLRNCOMPASS PathwaysNASDAQ:CMPSTheravance BiopharmaNASDAQ:TBPHView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 19,088 shares on 5/20/2024Ownership: 0.021%Ikarian Capital LLCBought 1,162,378 shares on 5/17/2024Ownership: 1.790%BVF Inc. ILBought 8,902,972 shares on 5/16/2024Ownership: 9.884%Janus Henderson Group PLCBought 6,993,007 shares on 5/16/2024Ownership: 7.763%Acadian Asset Management LLCSold 319,343 shares on 5/10/2024Ownership: 0.266%View All Institutional Transactions IMUX Stock Analysis - Frequently Asked Questions How have IMUX shares performed this year? Immunic's stock was trading at $1.50 at the beginning of the year. Since then, IMUX shares have decreased by 28.0% and is now trading at $1.08. View the best growth stocks for 2024 here. How were Immunic's earnings last quarter? Immunic, Inc. (NASDAQ:IMUX) issued its earnings results on Wednesday, May, 8th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.02. How do I buy shares of Immunic? Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Immunic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunic investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV), Moderna (MRNA), CymaBay Therapeutics (CBAY) and NIO (NIO). This page (NASDAQ:IMUX) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
